Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017082 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
A Phase 2 study of Colorectal Cancer, sponsored by Prologue Research International.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Study locations
NCT00017082: Completed Phase 2 study of Colorectal Cancer, sponsored by Prologue Research International.
NCT00017082 is a Phase 2 study of Colorectal Cancer that has completed, run by Prologue Research International. The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017082, a Phase 2 study of Colorectal Cancer, has completed, sponsored by Prologue Research International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have recurrent metastatic colorectal cancer.
Conditions Studied
Interventions
- DRUG oxaliplatin
Study Locations (10)
North Carolina
- Southeastern Medical Oncology Center - Goldsboro
- Raleigh Hematology/Oncology Associates - Wake Practice - Raleigh
Pennsylvania
- Pinnacle Health Hospitals - Harrisburg
- University of Pennsylvania Cancer Center - Philadelphia
District of Columbia
- Washington Cancer Institute - Washington D.C.
Florida
- Comprehensive Cancer Care Specialists of Boca Raton - Boca Raton
Kentucky
- Kentuckiana Cancer Institute - Louisville
Nebraska
- University of Nebraska Medical Center - Omaha
New York
- Veterans Affairs Medical Center - Albany - Albany
Tennessee
- Memphis Cancer Center - Memphis
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT00017082 record still lists
NCT00017082 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which oxaliplatin is the first listed.
NCT00017082 lists 10 locations in 8 states (North Carolina, Pennsylvania, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT00017082 about?
NCT00017082 is a clinical study titled "Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have recurrent metastatic colorectal cancer.
What is the current status of trial NCT00017082?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-04. Estimated completion is 2010-12.
What conditions does trial NCT00017082 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT00017082?
The interventions under investigation include: oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00017082?
This trial is sponsored by Prologue Research International, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00017082 being conducted?
This trial has 10 study locations across District of Columbia, Florida, Kentucky, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia